Cyclin-dependent kinase pathways as targets for women's cancer treatment

被引：29

作者：

Konecny, Gottfried E. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

来源：

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY | 2016年 / 28卷 / 01期

关键词：

abemaciclib (LY2835219) and ribociclib (LEE011); cyclin-dependent kinase 4 and 6 inhibition; palbociclib (PD0332991); 4/6 INHIBITOR PALBOCICLIB; ANTITUMOR-ACTIVITY; PD; 0332991; PD0332991; OVEREXPRESSION; EXPRESSION; TRIAL; AMPLIFICATION; PROLIFERATION; COMBINATION;

D O I：

10.1097/GCO.0000000000000243

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Purpose of reviewIn this article, we not only review the preclinical and clinical studies of cyclin-dependent kinase (CDK) 4/6 inhibitors in breast cancer, liposarcoma, mantel cell lymphoma, melanoma and germ cell tumors, but also examine promising preclinical data in glioblastoma, renal and ovarian cancer models that may provide directions for future development.Recent findingsTargeting CDKs has been the focus of considerable basic science and clinical research. The CDK 4/6 inhibitors are a novel class of therapeutics that target the CDK 4/6 kinases that promote transition through the cell cycle. Currently, palbociclib (PD0332991, Pfizer), abemaciclib (LY2835219, Lilly) and ribociclib (LEE011, Novartis) are being investigated in clinical trials. These oral agents offer the hope of clinical efficacy in many tumor types, and have been associated with minimal toxicity. Amplification/overexpression of cyclin D, loss of CDKN2A (p16) and amplification/overexpression of CDK4 are proposed biomarkers of improved response to CDK4/6 inhibition.SummaryPalbociclib, abemaciclib and ribociclib have demonstrated very promising clinical activity in breast cancer, liposarcoma, mantel cell lymphoma and melanoma. Moreover, CDK4/6 inhibitors have shown promising preclinical activity in glioblastoma, renal and ovarian cancer models that may provide directions for their future clinical development. Further preclinical and clinical research is needed to better understand mechanisms of resistance and develop rational combination therapies with other targeted agents.

引用

页码：42 / 48

页数：7

共 45 条

[1] Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy [J].

Barretina, Jordi ;

Taylor, Barry S. ;

Banerji, Shantanu ;

Ramos, Alexis H. ;

Lagos-Quintana, Mariana ;

DeCarolis, Penelope L. ;

Shah, Kinjal ;

Socci, Nicholas D. ;

Weir, Barbara A. ;

Ho, Alan ;

Chiang, Derek Y. ;

Reva, Boris ;

Mermel, Craig H. ;

Getz, Gad ;

Antipin, Yevgenyi ;

Beroukhim, Rameen ;

Major, John E. ;

Hatton, Charles ;

Nicoletti, Richard ;

Hanna, Megan ;

Sharpe, Ted ;

Fennell, Tim J. ;

Cibulskis, Kristian ;

Onofrio, Robert C. ;

Saito, Tsuyoshi ;

Shukla, Neerav ;

Lau, Christopher ;

Nelander, Sven ;

Silver, Serena J. ;

Sougnez, Carrie ;

Viale, Agnes ;

Winckler, Wendy ;

Maki, Robert G. ;

Garraway, Levi A. ;

Lash, Alex ;

Greulich, Heidi ;

Root, David E. ;

Sellers, William R. ;

Schwartz, Gary K. ;

Antonescu, Cristina R. ;

Lander, Eric S. ;

Varmus, Harold E. ;

Ladanyi, Marc ;

Sander, Chris ;

Meyerson, Matthew ;

Singer, Samuel .

NATURE GENETICS, 2010, 42 (08) :715-U103

[2]

Beà S, 2001, CANCER RES, V61, P2409

[3] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[4] ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human Phase I study. [J].

Bendell, Johanna C. ;

Patel, Manish ;

Infante, Jeffrey R. ;

Kurkjian, Carla ;

Jones, Suzanne ;

Pant, Shubham ;

Burris, Howard A. ;

Hainsworth, John D. ;

Moreno, Ofir ;

Moore, Kathleen .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)

[5]

BOSCH F, 1994, BLOOD, V84, P2726

[6]

BUCKLEY MF, 1993, ONCOGENE, V8, P2127

[7] p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells [J].

Cen, Ling ;

Carlson, Brett L. ;

Schroeder, Mark A. ;

Ostrem, Jamie L. ;

Kitange, Gaspar J. ;

Mladek, Ann C. ;

Fink, Stephanie R. ;

Decker, Paul A. ;

Wu, Wenting ;

Kim, Jung-Sik ;

Waldman, Todd ;

Jenkins, Robert B. ;

Sarkaria, Jann N. .

NEURO-ONCOLOGY, 2012, 14 (07) :870-881

[8] Overexpression of Cdk6-cyclin D3 highly sensitizes cells to physical and chemical transformation [J].

Chen, QH ;

Lin, J ;

Jinno, S ;

Okayama, H .

ONCOGENE, 2003, 22 (07) :992-1001

[9] CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment [J].

DeMichele, Angela ;

Clark, Amy S. ;

Tan, Kay See ;

Heitjan, Daniel F. ;

Gramlich, Kristi ;

Gallagher, Maryann ;

Lal, Priti ;

Feldman, Michael ;

Zhang, Paul ;

Colameco, Christopher ;

Lewis, David ;

Langer, Melissa ;

Goodman, Noah ;

Domchek, Susan ;

Gogineni, Keerthi ;

Rosen, Mark ;

Fox, Kevin ;

O'Dwyer, Peter .

CLINICAL CANCER RESEARCH, 2015, 21 (05) :995-1001

[10] Molecular Pathways: CDK4 Inhibitors for Cancer Therapy [J].

Dickson, Mark A. .

CLINICAL CANCER RESEARCH, 2014, 20 (13) :3379-3383

← 1 2 3 4 5 →